Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.53 |
| ▸ | FEN1 | P39748 | 2/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20281797 | 1.00 | ALOX5AP (0.53) | ALOX5APFEN1GPR119PIK3CDTRPV3 | |
| SCHEMBL21608119 | 0.86 | GPR119 (0.47) | ALOX5APFEN1GPR119PIK3CDKDM4E | |
| SCHEMBL21608118 | 0.86 | GPR119 (0.47) | ALOX5APFEN1GPR119PIK3CDKDM4E | |
| SCHEMBL20281888 | 0.85 | GPR119 (0.47) | ALOX5APFEN1GPR119PIK3CDKDM4E | |
| SCHEMBL20281426 | 0.84 | PIK3CD (0.47) | ALOX5APFEN1GPR119PIK3CDKDM4E | |
| SCHEMBL23791421 | 0.83 | GPR119 (0.55) | ALOX5APFEN1GPR119PIK3CDKDM4E | |
| SCHEMBL21608027 | 0.83 | PIK3CD (0.48) | ALOX5APFEN1GPR119PIK3CDFAAH | |
| SCHEMBL20281821 | 0.83 | PIK3CD (0.48) | ALOX5APFEN1GPR119PIK3CDFAAH | |
| SCHEMBL20281427 | 0.83 | GPR119 (0.44) | ALOX5APFEN1GPR119PIK3CDKDM4E | |
| SCHEMBL18782206 | 0.83 | GPR119 (0.48) | ALOX5APFEN1GPR119TRPV3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-30 | — | — | US | disclosed |
| WO-2019243531-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300900-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | ALOX5AP 1427/4885FEN1 333/4885GPR119 1166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.